



FW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Christopher J.M. Meade *et al.*

Examiner: Phyllis G. Spivack

Serial No.: 10/614,382

Group Art Unit: 1614

Filed: July 7, 2003

Docket: 1/1365

Customer No.: 28501

Confirmation No.: 7418

For: PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND  
EGFR KINASE INHIBITORS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY TO RESTRICTION REQUIREMENT**

Sir:

This Reply is filed in response to the Office Action dated August 11, 2004. In that Office Action, a one month shortened statutory period was set for response, and this Reply is therefore timely.

**Remarks**

Claims 1, 2, and 4 to 45, as amended, are pending.

In the Office Action, the Examiner imposed a restriction requirement in the instant application.

In response to that restriction requirement, applicants hereby elect with traverse Group I, claims 1, 2, 4 to 12, and 45.

Applicants, however, respectfully request that the Examiner reconsider and withdraw the restriction requirement as to all the claims for the reasons given below.

Group I and Groups II are related as pharmaceutical compositions and pharmaceutical compositions suitable for inhalation, respectively. Therefore, Group I and Group II are sufficiently related such that the search for relevant art for Group I would be expected to